Liqiang Wei

发表

Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI

H. Lv, J. Xian, Zhenchang Wang, 2016, Acta radiologica.

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase

Y. Piao, W. Sang, Jing Yang, 2022, Frontiers in Immunology.

Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study

Jing Yang, Lei Yang, Yiping Wu, 2020, Leukemia & lymphoma.

Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis

Jing Yang, Lei Yang, Yiping Wu, 2020, Leukemia & lymphoma.

Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals

Jing Yang, Liqiang Wei, Xin-di Liu, 2020, Aging Pathobiology and Therapeutics.

Case Report: Balanced Reciprocal Translocation t (17; 22) (p11.2; q11.2) and 10q23.31 Microduplication in an Infertile Male Patient Suffering From Teratozoospermia

Xiaodan Lv, Yu He, Liqiang Wei, 2022, Frontiers in Genetics.

SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.

Jing Yang, Lei Yang, Jingwen Wang, 2020, Leukemia research.

LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma

Y. Piao, Luo Zhang, Jing Yang, 2021, Theranostics.

Nasal type extranodal natural killer/T-cell lymphomaassociated hemophagocytic lymphohistiocytosis: A Case report and literature review

Jinguo Ye, Jing Yang, Liqiang Wei, 2022, Aging Pathobiology and Therapeutics.

Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

Jing Yang, Lei Yang, Jingwen Wang, 2020, Journal of Cancer Research and Clinical Oncology.

Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution

Y. Piao, Jing Yang, Liqiang Wei, 2023, Chinese medical journal.

Outcomes of patients treated with SVILE vs. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study

Jing Yang, Lei Yang, Yiping Wu, 2020, Cancer biology & medicine.

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma.

Y. Piao, Liqiang Wei, Xin-di Liu, 2023, Chinese medical journal.

Clinical-radiomic features predict survival in patients with extranodal nasal-type natural killer/T cell lymphoma

Xiaoxia Qu, J. Xian, Yuwei Xia, 2022, Chinese Journal of Academic Radiology.

Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center

Le Zhang, Lei Yang, Yiping Wu, 2017, International Journal of Hematology.

First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial

Li Ling, Panpan Liu, Jun Cai, 2024, The Lancet Haematology.

Toxic epidermal necrosis caused by programmed cell death protein 1 inhibitors in a patient receiving chimeric antigen receptor-T cell therapy

A. Wei, Liqiang Wei, Liang Wang, 2023, Chinese medical journal.

A novel prognostic model based on ferritin and nomogram‐revised risk index could better stratify patients with extranodal natural killer/T‐cell lymphoma

Y. Piao, W. Sang, Jing Yang, 2023, Cancer medicine.